Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14716347rdf:typepubmed:Citationlld:pubmed
pubmed-article:14716347lifeskim:mentionsumls-concept:C0000768lld:lifeskim
pubmed-article:14716347lifeskim:mentionsumls-concept:C0005961lld:lifeskim
pubmed-article:14716347lifeskim:mentionsumls-concept:C0231921lld:lifeskim
pubmed-article:14716347lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:14716347lifeskim:mentionsumls-concept:C1515895lld:lifeskim
pubmed-article:14716347lifeskim:mentionsumls-concept:C0443252lld:lifeskim
pubmed-article:14716347pubmed:issue5lld:pubmed
pubmed-article:14716347pubmed:dateCreated2004-2-24lld:pubmed
pubmed-article:14716347pubmed:abstractTextWe studied long-term pulmonary function testing (PFT) in a retrospective cohort of 6-month survivors of allogeneic marrow transplant (BMT) between 1980 and 1997. Of 593 patients, 73, 71 and 65% had adequate data to assess for obstruction, restriction and diffusion impairments respectively. Over 5 years, mean declines in 1-s forced expiratory volume/forced vital capacity (FEV1/FVC), total lung capacity (TLC) and diffusion were 4, 7 and 17%, respectively. TLC and diffusion tended to subsequently increase. In all, 6, 12 and 35% of patients met criteria for obstruction, restriction and impaired diffusion, respectively. Obstruction was less common in recent transplants (5 vs 15%, P=0.004), while restriction and diffusion impairment rates remained stable. There was significantly greater mortality with obstruction (HR 2.0 (1.04-3.95)), and a nonstatistically significant higher mortality rate with restriction (HR 1.6 (0.95-2.75)), but not with impaired diffusion (HR=0.99 (0.65-1.50)). cGVHD (OR 16.7 (2.2-129.8)) and busulfan (OR 2.9 (1.01-8.24)) were associated with obstruction. Marrow from nonsibling or mismatched donors (OR 4.9 (2.2-10.7)) was associated with restriction. In summary, after BMT, decreased diffusion capacity is common and benign; obstruction has decreased in frequency, is rare without cGVHD, and is associated with mortality; nonsibling and mismatched donor are risk factors for restriction.lld:pubmed
pubmed-article:14716347pubmed:languageenglld:pubmed
pubmed-article:14716347pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14716347pubmed:citationSubsetIMlld:pubmed
pubmed-article:14716347pubmed:statusMEDLINElld:pubmed
pubmed-article:14716347pubmed:monthMarlld:pubmed
pubmed-article:14716347pubmed:issn0268-3369lld:pubmed
pubmed-article:14716347pubmed:authorpubmed-author:ChanC KCKlld:pubmed
pubmed-article:14716347pubmed:authorpubmed-author:LiptonJ HJHlld:pubmed
pubmed-article:14716347pubmed:authorpubmed-author:MessnerH AHAlld:pubmed
pubmed-article:14716347pubmed:authorpubmed-author:LaupacisAAlld:pubmed
pubmed-article:14716347pubmed:authorpubmed-author:SzalaiJ PJPlld:pubmed
pubmed-article:14716347pubmed:authorpubmed-author:MarrasT KTKlld:pubmed
pubmed-article:14716347pubmed:issnTypePrintlld:pubmed
pubmed-article:14716347pubmed:volume33lld:pubmed
pubmed-article:14716347pubmed:ownerNLMlld:pubmed
pubmed-article:14716347pubmed:authorsCompleteYlld:pubmed
pubmed-article:14716347pubmed:pagination509-17lld:pubmed
pubmed-article:14716347pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:meshHeadingpubmed-meshheading:14716347...lld:pubmed
pubmed-article:14716347pubmed:year2004lld:pubmed
pubmed-article:14716347pubmed:articleTitleLong-term pulmonary function abnormalities and survival after allogeneic marrow transplantation.lld:pubmed
pubmed-article:14716347pubmed:affiliationJoint Division of Respirology, Department of Medicine, University Health Network and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. ted.marras@utoronto.calld:pubmed
pubmed-article:14716347pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14716347pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14716347lld:pubmed